Aster Capital Management’s Protagonist Therapeutics PTGX Stock Holding History
Bought
Maintained
Sold
Other funds holding PTGX
Aster Capital Management's PTGX Position: Q3 2026 in Review
Aster Capital Management opened a new position in Protagonist Therapeutics (PTGX) in Q3 2026: 42 shares worth $5.92K. The stake represents ﹤0.01% of the portfolio and ranks #825 among its holdings. This is a return to the name: Aster Capital Management previously reported a position in PTGX as recently as Q3 2025.
Aster Capital Management first reported a position in PTGX in Q1 2025 and has held it in 3 quarters since. The position peaked at $60.8K in Q1 2025. 380 funds tracked by Wall St. Rank hold PTGX as of Q3 2026.
- Aster Capital Management held 42 shares of Protagonist Therapeutics worth $5.92K as of Q3 2026.
- Protagonist Therapeutics was a new Aster Capital Management position in Q3 2026.
- Protagonist Therapeutics made up ﹤0.01% of Aster Capital Management's portfolio in Q3 2026, its #825 holding.
- Aster Capital Management first reported a position in Protagonist Therapeutics in Q1 2025 and has held it in 3 quarters since.
- Aster Capital Management's Protagonist Therapeutics position peaked at $60.8K in Q1 2025.
- 380 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2026.
Based on Aster Capital Management's 13F filing for Q3 2026, filed 12 Nov 2026.